Ainos (NASDAQ:AIMD) Director Chun-Jung Tsai Sells 27,718 Shares

Ainos, Inc. (NASDAQ:AIMD) Director Chun-Jung Tsai sold 27,718 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total value of $51,832.66. Following the completion of the sale, the director owned 658,199 shares in the company, valued at $1,230,832.13. This represents a 4.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Chun-Jung Tsai also recently made the following trade(s):

• On Friday, May 22nd, Chun-Jung Tsai sold 1,082 shares of Ainos stock. The stock was sold at an average price of $1.55, for a total transaction of $1,677.10.

Ainos Stock Performance

NASDAQ:AIMD traded down $0.60 on Wednesday, reaching $2.56. 1,873,740 shares of the company’s stock were exchanged, compared to its average volume of 893,030. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.55 and a quick ratio of 0.50. The firm has a market cap of $21.81 million, a price-to-earnings ratio of -0.89 and a beta of 2.29. Ainos, Inc. has a 52 week low of $1.26 and a 52 week high of $4.50. The stock has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.83.

Ainos (NASDAQ:AIMD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Institutional Investors Weigh In On Ainos

Several hedge funds and other institutional investors have recently modified their holdings of AIMD. Two Sigma Investments LP bought a new stake in shares of Ainos during the third quarter valued at about $80,000. Renaissance Technologies LLC increased its position in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares during the period. DRW Securities LLC increased its position in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares during the period. Finally, Mariner LLC bought a new stake in shares of Ainos during the fourth quarter valued at about $37,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.